Immunoextraction of CD25 Using Anti-CD25 Monoclonal Antibodies in Artificial Kidneys

Abstract:

The objectives of this study were to compare transport characteristics of the soluble interleukin-2 receptor (CD25) in haemodialyzers (high- and low flux) under equilibrium and sink conditions. Using an in vitro model high-flux polymethylmethacrylate (PMMA), high-flux cellulose acetate (CA), and low-flux polysulfone (PSF) dialyzer membranes were perfused with CD25 through the intracapillary space. Anti-CD25 antibodies added to the extracapillary space resulted in immunoextraction of CD25 after the system had reached steady-state. Results indicate that CD25 was efficiently cleared by both high-flux dialyzers but not the low-flux dialyzer. Furthermore, CD25 interaction with cellulose acetate membranes may promote formation of antigen-antibody lattice structures which disperse after antigen concentrations occur in excess. CD25 did not strongly adsorb to any of the membranes but its mass clearance was significantly enhanced by antibodies in the dialysate compartment. These studies demonstrated the utility of in vitro experiments to elucidate midsize molecule clearance during dialysis therapy.

• Periodical: Journal of Biomimetics, Biomaterials and Tissue Engineering (Volume 9)
• Pages: 93-99
• DOI: https://doi.org/10.4028/www.scientific.net/JBBTE.9.93
• Online since: January 2011
• Authors: Michael L. Branham
• Keywords: Adsorption, Cellulose Acetate, Facilitated Transport, High-Flux Dialysis, Poly(methyl methacrylate) (PMMA), Serum Soluble Interleukin-2 Receptor

References

[1] D.A. Cantrell and K.A. Smith: Science 1984; 224: 1312-1316.

[2] W.C. Greene and W.J. Leonard: Annual Review of Immunology 1986; 4: 69-95.

[3] Y.T. Minami et al: Annual Review of Immunology 1993; 11: 165-190.

[4] M.C. Miedel et al: Biochemical Biophysical Research Communications, 1988; 154(5): 372-379.

[5] L.A. Rubin and D.L. Nelson: Annals of Internal Medicine 1990; 113: 619-627.

[6] L.A. Rubin, G. Jay and D.L. Nelson: Journal of Immunology 1986; 137: 3841-3844.

[7] Y. Jacques et al: Journal of Immunology 1987; 139 : 2306-2316.

[8] L.A. Rubin et al: Journal of Immunology 1985; 35: 3172-3177.

[9] W.C. Greene et al: Annals of Internal Medicine 1986; 105: 560-572.

[10] N. Yorioka et al: American Journal of Nephrology 1990; 10: 181-185.

[11] J.H. Bertram, F.R. Jones, and J.P. Balint: Clinical Immunotherapy 1996; 6: 211-227.

[12] M.S. Hout, K.E. LeJeune, T.M. Schaack, D.K. Bristow, and W.J. Federspiel: ASAIO J 2000; 46: 702-706.

DOI: 10.1097/00002480-200011000-00010

[13] U.E. Nydegger, R. Rieben, and P. Mohacsi: Transfusion and Apheresis Science 2001; 24: 39-47.

DOI: 10.1016/s0955-3886(00)00129-6

[14] N. Braun and T. Bosch: Expert Opinion on Investigational Drugs 2000; 9: 2017-(2038).

[15] K.M. Schneider: Kidney International 1998; 53(64): S61-S65.

[16] G.C. Zucchelll et al: Clinical Chemistry 1990; 36(12): 2106-2109.